Jim Reddoch, PHD is Executive Vice President, Co-Head Research & Investments and Chief Scientific Officer at Royalty Pharma.

Jim has led the team at Royalty Pharma that focuses on sourcing and analyzing new investment opportunities and partnerships for over 10 years.

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since their founding in 1996, they have been pioneers in the royalty market, collaborating with innovators from academic institutions and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry’s leading therapies, including AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and nine development-stage product candidates.

Prior to joining Royalty Pharma in 2008, Jim was Head of Healthcare Research at FBR Capital Markets. Previously, he was a biotechnology analyst at Bank of America and CIBC World Markets. Jim serves on the board of Avillion, a London-based drug development company funded by Royalty Pharma and other investors, and on Memorial Sloan Kettering Cancer Center’s external review board for its Technology Development Fund. 

Jim Reddoch has a BA from Furman University, a PhD in biochemistry and molecular genetics from the University of Alabama, and was a postdoctoral fellow at Yale.